Synribo Approved to Treat Rare Leukemia

2012-Oct-26 

By -- Scott Roberts

FRIDAY, Oct. 26 (HealthDay News) -- Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Some 5,430 people will be diagnosed with CML this year, the U.S. National Institutes of Health estimates. Synribo has been sanctioned to treat cases in which two other specific anti-cancer drugs have failed to stop CML's progression, the FDA said Friday in a news release.

Synribo is designed to be injected twice daily in different regimens for a number of consecutive days until white blood cell counts normalize, the agency said.

The most common adverse reactions observed during clinical testing included anemia, a drop in infection-fighting white blood cells, nausea, weakness, fatigue and injection-site reaction.

Synribo is marketed by the Israeli drug maker Teva Pharmaceuticals, with U.S. headquarters in Frazer, Pa.

More information

The U.S. National Library of Medicine has more about CML.

HealthDay News

Copyright © 2012 HealthDay. All rights reserved.
The information in this article, including reference materials, are provided to you solely for educational or research purposes. Information in reference materials, are not and should not be considered professional health care advice upon which you should rely. Health care information changes rapidly and consequently, information in this article may be out of date. Questions about personal health should always be referred to a physician or other health care professional.